Trial
NCT05098405
First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Molecular Partners AG
Collaborators
—
Condition
Advanced Malignant Solid Tumor
Intervention
MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q3w regimen)
Why stopped
After completion of the dose-escalation part of the study, the safety profile of MP0317 in monotherapy is considered adequately characterized in the dose-escalation part of the study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-01-30